Similar articles

• Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.

  Reynolds SJ, Makumbi F, Newell K, Kiwanuka N, Ssebbowa P, Mondo G, Boaz I, Wawer MJ, Gray RH, Serwadda D, Quinn TC. Reynolds SJ, et al. Lancet Infect Dis. 2012 Jun;12(6):441-8. doi: 10.1016/S1473-3099(12)70037-3. Epub 2012 Mar 19. Lancet Infect Dis. 2012. PMID: 22433279 Free PMC article. Clinical Trial.
• HSV therapy and HIV-1 reduction.

  Martinez V, Caumes E. Martinez V, et al. N Engl J Med. 2007 May 31;356(22):2323; author reply 2324. doi: 10.1056/NEJMc076120. N Engl J Med. 2007. PMID: 17538093 No abstract available.
• Treating HIV infection with drugs for HSV-2 infection?

  Buvé A, Lynen L. Buvé A, et al. Lancet. 2010 Mar 6;375(9717):782-4. doi: 10.1016/S0140-6736(10)60097-9. Epub 2010 Feb 12. Lancet. 2010. PMID: 20153889 No abstract available.
• Management of neonatal herpes simplex virus infection.

  Kesson AM. Kesson AM. Paediatr Drugs. 2001;3(2):81-90. doi: 10.2165/00128072-200103020-00001. Paediatr Drugs. 2001. PMID: 11269641 Review.
• Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.

  Tyring SK, Baker D, Snowden W. Tyring SK, et al. J Infect Dis. 2002 Oct 15;186 Suppl 1:S40-6. doi: 10.1086/342966. J Infect Dis. 2002. PMID: 12353186 Review.